Healthcare / Pharmaceutical RetailersKOSDAQ
$4760.00
+30.00 (+0.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.5B · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$53.3B
P/E
18.2x
↓EV/EBITDA
13.5x
↑ROE
6.3%
↑Gross Margin
47.5%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.7%
FCF CAGR
-33.2%
FCF margin
7.2%
FCF / Net income
0.54x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $22.18B · net income $2.97B · FCF $1.61B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $22.18B | $22.18B | $21.63B | $19.31B | $21.09B |
| Net Income | $2.97B | $2.97B | $3.82B | $4.50B | $4.73B |
| EBITDA | $3.98B | $3.98B | $5.61B | $6.03B | $6.29B |
| EPS | 261.00 | 261.00 | 370.86 | 441.59 | 463.82 |
| Gross Margin | 47.5% | 47.5% | 56.8% | 50.5% | 46.7% |
| Operating Margin | 12.8% | 12.8% | 25.4% | 23.9% | 31.3% |
| Net Margin | 13.4% | 13.4% | 17.6% | 23.3% | 22.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.01 | 0.00 |
| Current Ratio | 4.87 | 4.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.61B | $1.61B | $3.54B | $4.38B | $5.39B |
| Returns | |||||
| ROE | 6.3% | 6.3% | 8.6% | 14.9% | 18.4% |
| Valuation | |||||
| P/E | 18.24 | 18.24 | 13.68 | — | — |
| EV/EBITDA | 13.54 | 13.54 | 9.39 | — | — |
| P/B | 1.15 | 1.15 | 1.17 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 2.6% | 2.6% | 12.0% | -8.4% | — |
| EPS Growth | -29.6% | -29.6% | -16.0% | -4.8% | — |
| Dividend Yield | 5.0% | 5.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
17.4%
EPS terminal req.
$422.37
Spread vs growth
-47.0%
5Y implied EPS CAGR
14.4%
EPS terminal req.
$511.07
Spread vs growth
-44.0%
10Y implied EPS CAGR
12.2%
EPS terminal req.
$823.08
Spread vs growth
-41.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.8%
Start / end P/E
14.1x → 18.2x
EPS bridge
370.86 → 261.00
Residual
-8.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.